BACKGROUND: Recent data indicate that among patients with gastro-oesophageal reflux disease (GORD) there is a subgroup with a higher disrupting burden of illness in terms of symptom frequency and overall impact. OBJECTIVE: The aim of this study was to evaluate the burden of disrupting versus non-disrupting GORD on individuals, healthcare providers and society. METHODS: Data were obtained from European (France, Germany, Italy, Spain and the UK) and US respondents in the 2007 National Health and Wellness Survey (NHWS). Respondents with GORD were classified as having disrupting or non-disrupting GORD based on self-reported symptom frequency, presence of night-time symptoms and medication usage. Disrupting GORD was defined as the presence of GORD symptoms on at least 2 days/week in addition to either night-time symptoms or use of prescribed/over-the-counter medication at least twice a week during the past month. RESULTS: Of 116 536 respondents included in the 2007 NHWS, 23% reported GORD symptoms; 39% of these were acknowledged as having disrupting GORD. These patients had higher healthcare resource utilization than those with non-disrupting disease. Respondents with disrupting GORD also had poorer health-related quality of life, greater impairments in health-related work productivity and absenteeism (all p < 0.05 vs non-disrupting GORD), and higher associated total medical costs. Overall, patients with physician-diagnosed GORD also had significantly lower health-related quality of life than self-diagnosed respondents (p < 0.05). CONCLUSIONS: GORD is a common disease that places a substantial burden on affected individuals and society. A high proportion of patients have disrupting GORD, which has significant adverse potential from both a clinical and an economic perspective.
BACKGROUND: Recent data indicate that among patients with gastro-oesophageal reflux disease (GORD) there is a subgroup with a higher disrupting burden of illness in terms of symptom frequency and overall impact. OBJECTIVE: The aim of this study was to evaluate the burden of disrupting versus non-disrupting GORD on individuals, healthcare providers and society. METHODS: Data were obtained from European (France, Germany, Italy, Spain and the UK) and US respondents in the 2007 National Health and Wellness Survey (NHWS). Respondents with GORD were classified as having disrupting or non-disrupting GORD based on self-reported symptom frequency, presence of night-time symptoms and medication usage. Disrupting GORD was defined as the presence of GORD symptoms on at least 2 days/week in addition to either night-time symptoms or use of prescribed/over-the-counter medication at least twice a week during the past month. RESULTS: Of 116 536 respondents included in the 2007 NHWS, 23% reported GORD symptoms; 39% of these were acknowledged as having disrupting GORD. These patients had higher healthcare resource utilization than those with non-disrupting disease. Respondents with disrupting GORD also had poorer health-related quality of life, greater impairments in health-related work productivity and absenteeism (all p < 0.05 vs non-disrupting GORD), and higher associated total medical costs. Overall, patients with physician-diagnosed GORD also had significantly lower health-related quality of life than self-diagnosed respondents (p < 0.05). CONCLUSIONS: GORD is a common disease that places a substantial burden on affected individuals and society. A high proportion of patients have disrupting GORD, which has significant adverse potential from both a clinical and an economic perspective.
Authors: Debra Lerner; Benjamin C Amick; Jennifer C Lee; Ted Rooney; William H Rogers; Hong Chang; Ernst R Berndt Journal: Med Care Date: 2003-05 Impact factor: 2.983
Authors: Scott Ramsey; Richard Willke; Andrew Briggs; Ruth Brown; Martin Buxton; Anita Chawla; John Cook; Henry Glick; Bengt Liljas; Diana Petitti; Shelby Reed Journal: Value Health Date: 2005 Sep-Oct Impact factor: 5.725
Authors: P Wahlqvist; M Karlsson; D Johnson; J Carlsson; S C Bolge; M-A Wallander Journal: Aliment Pharmacol Ther Date: 2008-02-29 Impact factor: 8.171
Authors: Julio Ponce; Vicente Garrigues; Lars Agréus; Erminio Tabaglio; Michael Gschwantler; Eliseo Güallar; Mónica Tafalla; Javier Nuevo; Jan G Hatlebakk Journal: Therap Adv Gastroenterol Date: 2011-01 Impact factor: 4.409
Authors: J Ponce; V Garrigues; L Agréus; E Tabaglio; M Gschwantler; E Guallar; M Tafalla; J Nuevo; J Hatlebakk Journal: Int J Clin Pract Date: 2012-07-16 Impact factor: 2.503
Authors: Harathi Yandrapu; Marek Marcinkiewicz; Cezary Poplawski; Kyung Han; Tomasz Zbroch; George Goldin; Irene Sarosiek; Zbigniew Namiot; Jerzy Sarosiek Journal: Am J Med Sci Date: 2015-05 Impact factor: 2.378
Authors: Min Hye Im; Jong Won Kim; Whan Sik Kim; Jie-Hyun Kim; Young Hoon Youn; Hyojin Park; Seung Ho Choi Journal: J Gastric Cancer Date: 2014-03-31 Impact factor: 3.720
Authors: Nils-Olov Stålhammar; Brennan M Spiegel; Helena Granstedt Löfman; Maria Karlsson; Peter Wahlqvist; Jørgen Næsdal; M Todd Nelson; Nicolas Despiégel Journal: Pragmat Obs Res Date: 2012-12-05